lilly glp 1 injection Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients Lilly hikes revenue forecasts on

A four-minute drive north of the Illinois-Wisconsin border in 'America's Dairyland,' Eli Lilly is staking one of its largest-ever manufacturing bets to continue its dominance in obesity drugs and support a deep pipeline of next-generation medicines for the most lucrative pharmaceutical market.

But while these medications can help reduce appetite, they also make it more...

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications

Design Scandinavian cohort study

Background: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk

Hello, Supergut